Autologous Immunoregulatory Dendritic Cells for Type 1 Diabetes Therapy

Phase 2 Withdrawn DiaVacs, Inc. Stanford University · collab University of Miami · collab University of Pittsburgh Medical Center · collab West Penn Allegheny Health System · collab

RandomizedCrossoverQuadruple-blindPrevention

Summary

The purpose of this study is to determine whether dendritic cells collected via leukapheresis and incubated with antisense DNA oligonucleotides and then injected back into the same subject will serve as modulators of the immune system in a manner that disrupts the autoimmune process responsible for the destruction of pancreatic beta cells in subjects with new onset type 1 diabetes.

Timeline

Start: 2015-10
Primary completion: 2024-02-16
Completion: 2024-02-16

Outcome

Outcome not reported

Stopped (Business): “Funding for study not procured.”

Publications

Phillips BE, Garciafigueroa Y, Engman C, Trucco M, Giannoukakis N. Tolerogenic Dendritic Cells and T-Regulatory Cells at the Clinical Trials Crossroad for the Treatment of Autoimmune Disease; Emphasis on Type 1 Diabetes Therapy. Front Immunol. 2019 Feb 6;10:148. doi: 10.3389/fimmu.2019.00148. eCollection 2019.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Immunoregulatory Dendritic Cells	Cell therapy	1e+07 cells	Other